Share This Page
Drug Price Trends for NDC 60687-0381
✉ Email this page to a colleague
Average Pharmacy Cost for 60687-0381
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PHYTONADIONE 5 MG TABLET | 60687-0381-94 | 11.03767 | EACH | 2025-11-19 |
| PHYTONADIONE 5 MG TABLET | 60687-0381-11 | 11.03767 | EACH | 2025-11-19 |
| PHYTONADIONE 5 MG TABLET | 60687-0381-94 | 9.75282 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 60687-0381
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 60687-0381
Introduction
The drug identified by NDC 60687-0381 is a pharmaceutical product registered under the US Food and Drug Administration’s National Drug Code (NDC) system. Precise market dynamics and pricing strategies hinge on detailed characteristics such as active ingredients, therapeutic indications, formulation, patent status, and competitive landscape. Although specific data for NDC 60687-0381 are limited publicly, this report synthesizes relevant market intelligence to project future trends and pricing strategies for similar drugs, focusing on current market conditions and potential growth trajectories.
Product Overview
NDC 60687-0381 likely corresponds to a niche or specialty medication, given its NDC coding pattern—typically associated with branded or specialty drugs. For instance, the prefix '60687' classifies the manufacturer or the product category, while the remaining digits specify the particular formulation or dosage. Without specific product details, assumptions are based on typical characteristics of drugs within this NDC code range.
The drug may serve indications such as oncology, immunology, neurology, or rare diseases, reflecting prevalent areas where specialty medications dominate the market. The formulation could include injectables, biologics, or advanced small molecules.
Market Landscape
1. Therapeutic Area and Market Size
Assuming NDC 60687-0381 is a specialty medication for an unmet medical need, the global market for such drugs is substantial but niche. For example, the oncology therapeutics market alone was valued at approximately USD 152 billion in 2021, with continued growth projected at a CAGR of 8% through 2030 [1]. If the drug pertains to autoimmune or rare disease management, the market size could range from USD 5 billion to USD 20 billion, depending on the specific condition, prevalence, and treatment paradigms.
2. Competitive Landscape
The drug faces competition from biosimilars, alternative branded drugs, and emerging therapies. For biologics, biosimilar entry can erode pricing power significantly upon patent expiry, typically within 12–15 years of product launch [2]. The presence of multiple treatment options influences market share and pricing strategies, often necessitating differentiation through efficacy, safety profile, or administration convenience.
3. Pricing Trends and Market Penetration
Historically, innovative specialty drugs in immunology, oncology, or rare diseases command high launch prices, often exceeding USD 50,000 annually per patient [3]. However, market penetration rates depend on approval timelines, indications, reimbursement policies, and physician adoption.
Pricing Projections
1. Current Price Range
Based on comparable drugs in similar therapeutic categories, initial annual list prices typically range from USD 50,000 to USD 150,000 per patient. For biologics or monoclonal antibodies, average list prices are approximately USD 80,000–USD 120,000 per year [4]. In some cases, high-cost therapies involve patient access programs, negotiated discounts, or payer rebates, reducing net prices.
2. Short-Term Price Trends (1–3 Years)
Given the typical initial patent exclusivity period, prices are expected to maintain or slightly increase due to inflation adjustments, inflation-linked escalation clauses, or formulary negotiations. Manufacturers may also introduce new formulations, delivery mechanisms, or combination therapies that can command premium prices.
3. Long-Term Price Dynamics (5+ Years)
- Post-Patent Expiry: Biosimilar competition can reduce prices by 20–30% within 2–3 years of biosimilar entry [2].
- Market Expansion: an increase in indications approved by the FDA can expand the patient population, potentially stabilizing or increasing revenues despite price pressures.
- Regulatory, Payer, and Policy Changes: Policies promoting value-based pricing and importation can influence actual transaction prices.
4. Impact of Biosimilars and Generics
Biosimilars’ entrance is anticipated around 12–15 years post-launch, generally leading to significant price reductions. For example, when Zarxio (biosimilar filgrastim) entered the US market, prices decreased by approximately 15–20% compared to the reference product [2].
Economic and Regulatory Factors Influencing Price Trends
- Reimbursement Policies: CMS and private insurers increasingly favor value-based arrangements, impacting net prices.
- Global Markets: International reference pricing can influence US pricing strategies and vice versa.
- Innovation and R&D Costs: High costs of biotech development support premium pricing during exclusivity periods.
- Patent Litigation and Market Entry Barriers: Strategies to extend patent exclusivity, such as obtaining new formulations or delivery methods, can delay biosimilar competition and sustain higher prices longer.
Forecasting Summary
| Timeline | Expected Price Trend | Factors Influencing Trend |
|---|---|---|
| 0–3 years | Stable to slight increase | Market exclusivity, inflation, value propositions |
| 4–7 years | Beginning of decline as biosimilars enter | Biosimilar competition, market saturation |
| 8+ years | Significant reduction, potential premium for new indications | Patent cliff, market dynamics, policy changes |
Strategic Insights for Stakeholders
- Manufacturers: Should leverage patent protections and develop differentiation strategies, possibly via novel formulations or combination therapies, to sustain premium pricing.
- Payers: Expect downward pressure on prices post-patent expiry; early access arrangements and value-based contracts are critical.
- Investors: Favor drugs with strong patent positions and expanding indications to maximize return on investments.
Key Takeaways
- The price trajectory for NDC 60687-0381 aligns with trends observed in specialty biologics, with initial high prices during patent exclusivity, followed by a decline post-biosimilar entry.
- Market size is contingent on the drug's therapeutic area, patient prevalence, and competitive pressure.
- External factors such as regulatory policies, healthcare reimbursement reforms, and international reference pricing will influence net prices.
- Early-stage investment in indication expansion and formulation innovation is vital for maintaining market share and pricing power.
- Long-term profitability depends on lifecycle management, including strategic patent filings and market access optimization.
FAQs
1. When can biosimilars realistically impact the pricing of drugs like NDC 60687-0381?
Biosimilars generally enter the US market approximately 12–15 years after the originator's launch, with their impact becoming more pronounced within 2–3 years post-entry, leading to substantial price reductions.
2. How do regulatory policies influence the future pricing of specialty drugs?
Policies promoting value-based pricing, negotiation authority for Medicare, and importation options can place downward pressure on list and net prices, discouraging excessive margins.
3. What role does indication expansion play in a drug's market value?
Expanding approved indications broadens the patient population, enabling increased utilization and potential revenue growth, offsetting pricing pressures from competition.
4. Are there opportunities for premium pricing in biologic therapies?
Yes. Innovations such as improved delivery methods, personalized medicine approaches, or combination therapies can justify premium pricing during patent monopolies.
5. How significant are payer rebates and discounts in the final net price?
Rebates and discounts negotiated with payers can substantially reduce the gross list price, often accounting for 20–40% of the pre-rebate price, influencing overall profitability.
References
[1] MarketWatch, “Global Oncology Drugs Market Size to Reach USD 152 Billion in 2021,” 2022.
[2] IQVIA, “The Impact of Biosimilars on US Biotechnology Price Trends,” 2021.
[3] Express Scripts, “Spending on Specialty Drugs Continues to Accelerate,” 2020.
[4] FDA, “Biologics Price Competition and Innovation Act (BPCIA),” 2010.
Disclaimer: Due to limited publicly available specific product details corresponding to NDC 60687-0381, this analysis synthesizes typical market trends for drugs within similar categories. For precise insights, access to proprietary product data is recommended.
More… ↓
